Clinical Trials Logo

Filter by:
NCT ID: NCT00326976 Completed - Clinical trials for Myocardial Infarction

Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate whether FX06 is capable of limiting infarct size following balloon catheterization for acute myocardial infarction.

NCT ID: NCT00324311 Completed - Burn Clinical Trials

Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care

Start date: December 2005
Phase: Phase 3
Study type: Interventional

Burns represent one of the most severe and dreaded traumas. Burned and traumatized tissue is known as eschar. The dead eschar, if not removed, often becomes heavily contaminated and is the source of local and/or systemic infection or sepsis. The local inflammation and infection destroy healthy surrounding tissues and extends the original damage. In order to prevent these complications, and in order to minimize the risk of infection, it is imperative to evaluate the burn and remove all of the offending eschar at the earliest possible opportunity. This removal of dead tissue is termed "debridement". The most direct debridement method for eschar removal is surgery. Traditional, conservative non-surgical debridement is a lengthy process which often involves many complications. The objective of this study is to evaluate the safety and enzymatic debriding efficacy of Debrase Gel Dressing (DGD) in hospitalized patients with deep partial thickness and/or full thickness thermal burns and to compare DGD to standard of care (SOC).

NCT ID: NCT00324051 Completed - Schizophrenia Clinical Trials

Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

PREFERENCE
Start date: May 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to estimate drug preference of stable schizophrenic patients who will be treated with olanzapine orodispersible tablets for 6 weeks then with olanzapine tablets for 6 weeks and vice-versa.

NCT ID: NCT00322595 Completed - Clinical trials for Generalized Anxiety Disorder

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder

SILVER
Start date: May 2006
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

NCT ID: NCT00320489 Completed - Schizophrenia Clinical Trials

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

Start date: April 2006
Phase: Phase 3
Study type: Interventional

To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.

NCT ID: NCT00319709 Completed - Depressive Disorder Clinical Trials

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression

ZEPHIR
Start date: April 2006
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly patients with depression. The secondary objectives are to evaluate the safety of SR58611A and to evaluate the efficacy of SR58611A on disability and quality of life in elderly patients with depression.

NCT ID: NCT00318461 Completed - Clinical trials for Diabetes Mellitus, Type 2

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together

LEAD-2
Start date: May 2006
Phase: Phase 3
Study type: Interventional

This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of metformin monotherapy and combination therapy of metformin and glimepiride. Two trial periods: A 6 month (26 weeks) randomised, double-blinded period followed by an 18 months open-label extension, in total 2 years (104 weeks).

NCT ID: NCT00318422 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

LEAD-1
Start date: May 2006
Phase: Phase 3
Study type: Interventional

This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride.

NCT ID: NCT00317395 Completed - Coronary Disease Clinical Trials

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

SEPIA-ACS1
Start date: June 2006
Phase: Phase 2
Study type: Interventional

Primary objective: To demonstrate the clinical efficacy of otamixaban (dose effect via 5 intravenous [IV] regimens) in patients with moderate-to-high-risk non-ST elevation acute coronary syndromes (ACS) and planned early invasive strategy. Secondary objectives: To evaluate safety and assess pharmacokinetics (PK) and pharmacodynamics (PD).

NCT ID: NCT00314288 Completed - Parkinson's Disease Clinical Trials

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).